Skip to content
After bottoming at $10 earlier this month, investor interest soared in the last week for Inovio Pharmaceuticals (NASDAQ:INO). The company posted a corporate overview on its DNA medicines, increasing buying volume in INO stock.Source: Ascannio / Shutterstock.com What did Inovio say about its DNA Medicines?In Inovio's investor presentation, the company highlighted its proprietary smart device delivering plasmids. Already, it demonstrated a safe and robust immune response in more than 2,000 patients.InvestorPlace - Stock Market News, Stock Advice & Trading Tips DNA Medicine Lifts INO StockThe main DNA vaccines highlighted (slide 3) include the INO-4800, a Covid-19 vaccine. This vaccine showed long-term protection against live viruses in non-hospitalized patients 13-weeks after vaccination.Inovio's INO-4700 is the first vaccine for Middle East Respiratory Syndrome in Phase 2. This is a highly fatal virus. So, if Inovio continues to post positive developments from the clinical results, biotech investors will continue buying Inovio stock. * 7...
Yahoo Finance’s Jessica Smith joins the On the Move panel to discuss the latest on a Stimulus Bill deal as well as Pres. Trump’s stance on transfer of power.
...
GoodRx, widely known for its discounts at the point of sale for prescriptions, is looking at the value the market is providing the industry -- and wants a slice....
Mark Tulay, Test of Corporate Purpose Founder & CEO joins the On the Move panel to discuss the Test of Corporate Purpose Initiative and the results of a recent survey....
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can do a lot better......
If anyone had told you in January what this year would have in store, you would have worried about their mental condition. Now, we're all worrying about our own.A crazy market. The terrible toll of the novel coronavirus. A brutal election campaign. Lockdowns. Huge unemployment. The race for a vaccine.And that's just the tip of the iceberg.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo far, September has been more about profit taking as the third quarter winds down rather than extending the rally. The challenge is, since the stock market is forward looking, seeing six months down the road is getting a bit tougher to see.Will there be a vaccine? Who will win the elections? Will there be a second wave along with the regular flu season? * 7 Hot Stocks to Buy on Robinhood Now Investors are taking some profits off the table. But there are still some...
Stephanie Pierce - CEO of BNY Mellon Investment Management’s ETF and Index Business joins Yahoo Finance's On The Move panel to discuss how ETFs are faring amid the pandemic....
